Protagenic Therapeutics, Inc.

Equities

PTIX

US74365N2027

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 10:43:43 07/06/2024 pm IST			5-day change	1st Jan Change
1.05 ^USD	-2.78%		-20.45%	+6.06%

15/05	Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01/05	Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial	CI

Atrinsic, Inc. Creases Robert Ziroyan as Interim President and Chief Operating Officer

April 08, 2016 at 12:50 am IST

Atrinsic, Inc. announced that effective April 4, 2016, Robert Ziroyan ceased serving as interim President and Chief Operating Officer. Mr. Ziroyan's agreement with the company expired on December 31, 2015.

Latest news about Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial	01/05	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders	27/03	CI
Protagenic Therapeutics Achieves First Clinical Safety Milestone with Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders	13/02	CI
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12	MT
Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	12/12	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director	29/22/29	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	08/22/08	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/21/16	CI
Maxim Group Starts Protagenic Therapeutics at Buy with $4 Price Target	29/21/29	MT
Certain Warrant of Protagenic Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2021.	24/21/24	CI
Certain Common Stock of Protagenic Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2021.	24/21/24	CI
Certain Stock Options of Protagenic Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2021.	24/21/24	CI
Protagenic Therapeutics, Inc. Announces Audit Committee Changes	06/21/06	CI
Transcript : Protagenic Therapeutics, Inc. - Special Call	08/21/08
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	17/21/17	CI
Protagenic Therapeutics : Expects to Refile New Drug Application in Q4 After Implementing Change Requested by FDA	24/21/24	MT

Chart Protagenic Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTAGENIC THERAPEUTICS, INC.	+6.06%	4.79M
MODERNA, INC.	+52.91%	59.28B
LONZA GROUP AG	+41.42%	40.94B
IQVIA HOLDINGS INC.	-5.23%	40.17B
CELLTRION, INC.	-5.16%	28.69B
ICON PUBLIC LIMITED COMPANY	+12.98%	26.63B
ALNYLAM PHARMACEUTICALS, INC.	-20.96%	18.89B
MEDPACE HOLDINGS, INC.	+30.72%	12.46B
BIO-TECHNE CORPORATION	+0.79%	12.42B
UNITED THERAPEUTICS CORPORATION	+26.62%	12.26B

Other Biotechnology & Medical Research